APPLICATION NUMBER:
21-864

CHEMISTRY REVIEW(S)
Addendum to CMC Review #2 of NDA 21-864

From: Donna F. Christner, Ph.D.
To: NDA 21-864
Date: 18-May-2007
Subject: CMC evaluation of DMETS labeling comments dated 18-May-2007

Background

DMETS has submitted a final labeling review. Comments are evaluated as follows.

Recommendation and Conclusions on Approvability:

No action is indicated on DMETS comments. From a CMC standpoint, the NDA can be APPROVED. DMETS comments are reproduced below, followed by CMC evaluation.

DMETS comment 1:

1. Ensure that the established name is one-half the size of the proprietary name. See 21 CFR 201.10(g)(2).

CMC Evaluation: This issue was addressed in CMC review # 1, dated 17-May-2006. Sponsor replied and it was determined that the size of the established name as compared to the proprietary name is adequate. See CMC Review # 1.

DMETS Comment 2:

2. Revise the established name and product strength on all labels and labeling to read:

CMC Evaluation: Sponsor has been advised in April 2007 to change the µg to mcg. Sponsor agreed in Amendment 048, dated 04-May-2007 to change all future labels after use of the first batch and report this change in the Annual Report. This is acceptable. See CMC Review # 2, dated 08-May-2007.

Appears This Way
On Original
DMETS Comment 3:

3. Throughout the labels and labeling, delete ___ graphic art (as indicated by the arrow below) following the proprietary name as it distracts attention away from important statements such as the proprietary name, established name, and product strength.

CMC Evaluation: The ___ graphic does not interfere with the readability of the proprietary name, established name or strength, therefore, CMC does not have a comment on the graphic. Any decision or negotiation on the graphic will be a decision for the clinical division.

DMETS comment 4:

I. ClickCase Single Unit Dispenser

DMETS has identified the following potential safety concern regarding the Single Unit Dispenser. After a preliminary overview of the device, DMETS has concerns about the potential for damage to the device, spring, or casing of this item (e.g. misalignment of the spring and subsequent inability to dispense the medication, cracking and breaking of the plastic case). DMETS questions the durability of the device under routine handling, and how the patient would dispense the medication if the device is damaged or becomes non-operational at any time. Additionally, has any usability testing been performed on the device? Please forward our concerns to the CDRH reviewer.

This issue was addressed in CMC review #1. Wyeth responded favorably to the request. The following evaluation is taken from CMC Review #1, dated 17-May-2006.

Wyeth response: The is known for its strength and impact resistance. Testing as per 16CFR Part 1501, Choking Aspiration and Ingestion Hazard was performed on the dispenser and passed. Quality Assurance process controls are in place to ensure that the spring is present and oriented properly, the pill ring is oriented properly and the unit is functional. A camera vision system is used for this. In addition, if the unit is not functional, it can be returned to the pharmacist.

Evaluation: Acceptable.

Appears This Way On Original
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Donna Christner
5/18/2007 01:35:13 PM
CHEMIST

Addendum that you okayed

Moo-Jhong Rhee
5/18/2007 01:45:34 PM
CHEMIST
Chief, Branch III
NDA 21-864

Lybrel

Levonorgestrel and Ethinyl Estradiol Tablets

Wyeth Pharmaceuticals, Inc.

for
Division of Reproductive and Urologic Products

Donna F. Christner, Ph.D.

Office of New Drug Quality Assessment
Pre-Marketing Division II, Branch III
Table of Contents

Table of Contents .................................................................................................................. 2
Chemistry Review Data Sheet ................................................................................................. 3
The Executive Summary ........................................................................................................... 8
  I. Recommendations ............................................................................................................. 8
    A. Recommendation and Conclusion on Approvability ...................................................... 8
    B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk
       Management Steps, if Approvable ................................................................................. 8
  II. Summary of Chemistry Assessments ............................................................................. 8
    A. Description of the Drug Product(s) and Drug Substance(s) ........................................ 8
    B. Description of How the Drug Product is Intended to be Used ..................................... 10
    C. Basis for Approvability or Not-Approval Recommendation ...................................... 10
  III. Administrative .................................................................................................................. 10
    A. Reviewer’s Signature .................................................................................................... 10
    B. Endorsement Block ..................................................................................................... 10
    C. CC Block ..................................................................................................................... 10

Chemistry Assessment .......................................................................................................... 11
  I. Review Of Common Technical Document-Quality (Ctd-Q) Module 3.2: Body Of Data ...... 11
    S DRUG SUBSTANCE [Ethinyl Estradiol, Schering AG; ....................................................... 11
       Levonorgestrel, Schering AG] ......................................................................................... 11
    P DRUG PRODUCT [Lybrel, Oral tablet] ......................................................................... 12
    A APPENDICES ............................................................................................................. 41
    R REGIONAL INFORMATION ......................................................................................... 41
  II. Review Of Common Technical Document-Quality (Ctd-Q) Module 1 ............................ 45
    A. Labeling & Package Insert ......................................................................................... 45
    B. Environmental Assessment Or Claim Of Categorical Exclusion ................................... 45
  III. List Of Deficiencies To Be Communicated .................................................................... 45
Chemistry Review Data Sheet

1. NDA 21-864
2. REVIEW #: 2
3. REVIEW DATE: 08-May-2007
4. REVIEWER: Donna F. Christner, Ph.D.
5. PREVIOUS DOCUMENTS:

<table>
<thead>
<tr>
<th>Previous Documents</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original</td>
<td>27-May-2005</td>
</tr>
<tr>
<td>Amendment 003 (Withdrawn)</td>
<td>28-Nov-2005</td>
</tr>
<tr>
<td>Amendment 004 (Portions Withdrawn)</td>
<td>21-Dec-2005</td>
</tr>
<tr>
<td>Amendment 007</td>
<td>27-Jan-2006</td>
</tr>
<tr>
<td>Amendment 009</td>
<td>08-Feb-2006</td>
</tr>
<tr>
<td>Amendment 010 (Lybrel tradename)</td>
<td>10-Feb-2006</td>
</tr>
<tr>
<td>Amendment 013 (Meeting request/Level 3 change)</td>
<td>06-Mar-2006</td>
</tr>
<tr>
<td>Amendment 016 (Wyeth meeting minutes)</td>
<td>16-Mar-2006</td>
</tr>
<tr>
<td>Amendment 017 (Label icon)</td>
<td>21-Mar-2006</td>
</tr>
<tr>
<td>Amendment 019 (BCS Class 1 documentation)</td>
<td>24-Mar-2006</td>
</tr>
<tr>
<td>Amendment 022 (SUD/ClickCase Labeling)</td>
<td>29-Mar-2006</td>
</tr>
<tr>
<td>Amendment 023 (PI Labeling)</td>
<td>05-Apr-2006</td>
</tr>
<tr>
<td>Amendment 024 (Dial Pack Labeling)</td>
<td>20-Apr-2006</td>
</tr>
<tr>
<td>Amendment 026 (Reversion)</td>
<td>02-May-2006</td>
</tr>
</tbody>
</table>

6. SUBMISSION(S) BEING REVIEWED:

<table>
<thead>
<tr>
<th>Submission(s) Reviewed</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amendment 029 (Manufacturing change)</td>
<td>22-May-2006</td>
</tr>
<tr>
<td>Amendment 030 (Stability Data)</td>
<td>22-Jun-2006</td>
</tr>
<tr>
<td>Amendment 033 (Meeting Request)</td>
<td>18-Jul-2006</td>
</tr>
<tr>
<td>Amendment 037 (Complete Response to AE letter)</td>
<td>21-Aug-2006</td>
</tr>
<tr>
<td>Amendment 038 (Updated methods)</td>
<td>02-Oct-2006</td>
</tr>
<tr>
<td>Amendment 040 (Intent to Amend)</td>
<td>01-Nov-2006</td>
</tr>
<tr>
<td>Amendment 042</td>
<td>22-Dec-2006</td>
</tr>
<tr>
<td>Amendment 043 (Removal of Statement from wallet)</td>
<td>02-Feb-2007</td>
</tr>
<tr>
<td>Amendment 044 (Updated eCTD links for final carton labels)</td>
<td>15-Mar-2007</td>
</tr>
<tr>
<td>Amendment 048 (Commitment to change µg to mcg on all cartons after first batch utilized—Annual Reportable change)</td>
<td>04-May-2007</td>
</tr>
</tbody>
</table>
7. NAME & ADDRESS OF APPLICANT:

Name: Wyeth Pharmaceuticals, Inc
Address: PO Box 8299
         Philadelphia, PA 19101-8299
Representative: Randall B. Bremmer
Telephone: 484-865-3792

8. DRUG PRODUCT NAME/CODE/TYPE:

a) Proprietary Name: Lybrel
b) Non-Proprietary Name (USAN): Levonorgestral /Ethinyl estradiol
c) Code Name/# (ONDQA only): N/A
d) Chem. Type/Submission Priority (ONDQA only):
   • Chem. Type: 5
   • Submission Priority: S

9. LEGAL BASIS FOR SUBMISSION: 505(b)(1)

10. PHARMACOL. CATEGORY: Oral Contraceptive

11. DOSAGE FORM: Tablet (for continuous use)

12. STRENGTH/POTENCY: 90 µg Levonorgestrel (LNG)/
             20 µg Ethinyl Estradiol (EE)

13. ROUTE OF ADMINISTRATION: Oral

14. Rx/OTC DISPENSED:  _x_ Rx  ____OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
    _____SPOTS product – Form Completed
    _x_ Not a SPOTS product
16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

**Ethynyl estradiol**

![Ethynyl estradiol molecule](image)

Compendial name: Ethynyl Estradiol, USP  
Chemical names:  
19-Nor-17α-pregn-1,3,5(10)-triene-20-yne-3,17-diol (IUPAC)  
19-Norpregn-1,3,5(10)-triene-20-yne-3,17-diol, (17α)- (CAS)  
19-Ethynyl-estr-1,3,5(10)-triene-3,17β-diol (WHO)  
17α-Ethynyl-1,3,5(10)-stratriene-3,17-diol

USAN: Ethynyl Estradiol  
INN: Ethinylestradiol  
Laboratory code: AY-3877  
CAS Registry No: 57-63-6  
Molecular formula: C_{20}H_{24}O_{2}  
Molecular weight: 296.40

**Levonorgestral**

![Levonorgestral molecule](image)

Compendial name: Levonorgestrel, USP  
Chemical names:  
(-)-13β-Ethyl-17β-hydroxy-18,19-dinor-17α-pregn-4-en-20-yn-3-one (IUPAC)  
(-)-13-Ethyl-17-hydroxy-18,19-dinor-17α-pregn-4-en-20-yn-3-one  
D(-)-13-Ethyl-17-hydroxy-18,19-dinor-17α-pregn-4-en-20-yn-3-one (WHO)  
18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-,(17α)-(-)-  
(CAS Index)

USAN: Levonorgestrel  
INN: Levonorgestrel  
Laboratory code: WY-5104  
CAS Registry No: 797-63-7  
Molecular formula: C_{21}H_{28}O_{2}  
Molecular weight: 312.45
17. RELATED/SUPPORTING DOCUMENTS:

### A. DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER</th>
<th>ITEM REFERENCED</th>
<th>CODE</th>
<th>STATUS</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>4178</td>
<td>II</td>
<td>Schering</td>
<td>Levonorgestrel</td>
<td>1</td>
<td>Adequate</td>
<td>07-Feb-2006</td>
<td>Reviewed by R. Agarwal for NDA 21-871</td>
</tr>
<tr>
<td>1985</td>
<td>II</td>
<td>Schering</td>
<td>Ethinyl estradiol</td>
<td>3</td>
<td>Adequate</td>
<td>21-Nov-2005</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IV</td>
<td></td>
<td></td>
<td>1</td>
<td>Adequate</td>
<td>27-Jun-2005</td>
<td></td>
</tr>
<tr>
<td></td>
<td>III</td>
<td></td>
<td></td>
<td>3</td>
<td>Adequate</td>
<td>18-Nov-1996</td>
<td>Reviewed by R. Seevers for NDA 20-683</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td></td>
<td></td>
<td>1</td>
<td>Adequate</td>
<td>31-Jan-2006</td>
<td></td>
</tr>
<tr>
<td></td>
<td>III</td>
<td></td>
<td></td>
<td>4</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>III</td>
<td></td>
<td></td>
<td>1</td>
<td>Adequate</td>
<td>31-Jan-2006</td>
<td></td>
</tr>
<tr>
<td></td>
<td>III</td>
<td></td>
<td></td>
<td>1</td>
<td>Adequate</td>
<td>30-May-2003</td>
<td>Reviewed by L. Rocca for NDA 21-323</td>
</tr>
</tbody>
</table>

1. Action codes for DMF Table:
   1 – DMF Reviewed.
   Other codes indicate why the DMF was not reviewed, as follows:
   2 – Type 1 DMF
   3 – Reviewed previously and no revision since last review
   4 – Sufficient information in application
   5 – Authority to reference not granted
   6 – DMF not available
   7 – Other (explain under "Comments")

2. Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)
B. Other Documents:

<table>
<thead>
<tr>
<th>DOCUMENT</th>
<th>APPLICATION NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

18. STATUS:

<table>
<thead>
<tr>
<th>CONSULTS/CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biometrics</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EES</td>
<td>Acceptable</td>
<td>16-Jan-2007</td>
<td>J. D’Ambrogio</td>
</tr>
<tr>
<td>Pharm/Tox</td>
<td>Leachable limit ACCEPTABLE</td>
<td>22-Mar-2007</td>
<td>Leslie McKinney</td>
</tr>
<tr>
<td>Biopharm</td>
<td>BE study ACCEPTABLE</td>
<td>20-Mar-2007</td>
<td>Sandra Suarez-Sharp</td>
</tr>
<tr>
<td>LNC</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td>Will be submitted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMETS</td>
<td>Tradename acceptable</td>
<td></td>
<td>L. Wisniewski</td>
</tr>
<tr>
<td>EA</td>
<td>Granted</td>
<td>31-Mar-2006</td>
<td>D. Christner</td>
</tr>
<tr>
<td>Microbiology</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Appears This Way
On Original
The Chemistry Review for NDA 21-864

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

This NDA can be APPROVED from the CMC standpoint.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

Not applicable.

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

Lybrel is an oral contraceptive that contains two drug substances: levonorgestrel and ethinyl estradiol. Levonorgestrel is contained in the drug product at 90 μg and ethinyl estradiol at 20μg.

The sponsor is Wyeth Pharmaceuticals. The drug substances are manufactured by Schering and information is provided in DMFs 4178 and 1985.

DRUG SUBSTANCES

Levonorgestrel

Complete information on levonorgestrel is contained in Schering’s DMF # 4178. The DMF was reviewed for this NDA and found to be adequate.

General information, General Properties, and Batch Analysis of lots used to manufacture the clinical batches are included in the original NDA submission.

Ethinyl estradiol

Complete information on ethinyl estradiol is contained in Schering’s DMF 1985. The most recent review of the DMF was done by R. Agarwal (Review # 8, dated 21-Nov-2005) and found adequate.

General information, General Properties, and Batch Analysis of lots used to manufacture the clinical batches are included in the original NDA submission.
DRUG PRODUCT

The drug product is a continuous-use oral contraceptive (no pill-free period). The formulation is based on the company's approved product, Alesse, with a few changes. For the formulation, the amount of Levonorgestrel has been decreased from 100 μg to 90μg. In the original application, the tablets were manufactured by a method. Due to inadequate bridging of the clinical supplies manufactured by a method to the to-be-marketed tablets manufactured via , and the sponsor's reluctance to perform a BE study for this change, the sponsor opted to return to the manufacturing method late in the review cycle. It was agreed that the revision was allowed, but supporting data arrived too late for review, so the NDA received an AE action. In the complete response dated 21-Aug-2006, the sponsor submitted all required data for evaluation of the manufacturing method. On 22-Dec-2006, the sponsor submitted a major Amendment, changing the manufacturing method to method, submitting the required BE study to bridge tablets, and adequate stability data. Therefore, the to-be-marketed tablets will be manufactured according to the method, which have been shown to be bioequivalent to the clinical supply tablets.

The drug product is packaged in a Single Unit Dispenser which holds 28 active tablets containing 90μg levonorgestrel and 20μg ethinyl estradiol. The drug product is a yellow, biconvex, film-coated tablet debossed with “W” on one side and “1117” on the other side. Excipients in the tablet core include Micocrystalline Cellulose, Lactose monohydrate, Magnesium stearate, and Polacrilin potassium, Hypermellose, Titanium Dioxide, Polyethylene glycol 400, Iron Oxide, Polyethylene glycol 1450 and Montanic Ester Wax.

Regulatory specifications for the tablets include Appearance & Description, Identification A (HPLC), Identification B (Melting range for LNG), Strength, Degradation products, Content Uniformity and Dissolution. Acceptance criteria are set based on the approved specifications for Alesse. The methods for Strength, Degradation Products and Dissolution have been modified since the first review cycle to allow routine identification of potential packaging leachables.

The drug product is packaged in the Single Unit Dispenser (SUD). The sponsor has submitted 20 months of real-time stability data on tablets manufactured by the method, and has requested 24 months of expiry based on this submitted data. Based on analysis of the submitted data, 24 months of expiry can be granted. Tablets are to be stored at 25°C (77°F) with excursions permitted to 15-30°C (59-86°F).
EXECUTIVE SUMMARY SECTION

The sponsor submitted two comparability protocols for post-approval changes in the original application and two additional comparability protocols in the 22-Dec-2006 Amendment:

- Comparability Protocol for Packaging of the Single Unit Dispenser
- Comparability Protocol for the Replacement or Deletion of Montanic Ester Wax
- Comparability Protocol for Foil-Based Component Interchangeability
- Comparability Protocol for Blister Films Interchangeability

The Montanic Ester Wax protocol requests a supplement category of CBE-30, while the packaging/packaging component protocols request a category of Annual Report. All four comparability protocols can be approved.

B. Description of How the Drug Product is Intended to be Used

Lybrel is packaged in the Single Unit Dispenser. For the SUD, delivery of the pill is accomplished by squeezing the Dispenser to move the pill into an opening, where it is then dropped into the hand. Release of the Dispenser moves the next pill into place. No protective blister is in place during use. One pill is to be taken daily, in a continuous-use regimen (no pill-free day). Each package contains 28 active tablets. After one package is finished, the next package is started the following day.

C. Basis for Approvability or Not-Approval Recommendation

In the Complete Response, the sponsor provided all requested information on the manufacturing method and drug supplies for evaluation. Because of submission of the 22-Dec-2006 Amendment changing to the method and the adequate BE study comparing the and tablets, evaluation of the NDA was based on the data used to support the process. The sponsor has demonstrated that the manufacturing process is robust and the release specifications adequately control the quality of the drug product. Stability data supports granting of a 24 month expiry when stored at 25°C (77°F) with excursions permitted to 15-30°C (59-86°F).

III. Administrative

A. Reviewer's Signature

B. Endorsement Block

Donna F. Christner, Ph.D./Date: 18-Apr-2007
Moo-Jhong Rhee, Ph.D./Date
John Kim/Date

C. CC Block
40 Page(s) Withheld

6 Trade Secret / Confidential

Draft Labeling

Deliberative Process
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Donna Christner
5/15/2007 01:17:43 PM
CHEMIST

As we discussed and per your request, made minor changes.

Moo-Jhong Rhee
5/15/2007 02:49:50 PM
CHEMIST
Chief, Branch III
NDA 21-864

Lybrel

Levonorgestrel and Ethinyl Estradiol Tablets

Wyeth Pharmaceuticals, Inc.

for
Division of Reproductive and Urologic Products

Donna F. Christner, Ph.D.
Office of New Drug Quality Assessment
Pre-Marketing Division II, Branch III
# Table of Contents

Table of Contents .................................................................................................................. 2

Chemistry Review Data Sheet ................................................................................................. 4

The Executive Summary ......................................................................................................... 9

I. Recommendations ................................................................................................................. 9
   A. Recommendation and Conclusion on Approvability ..................................................... 9
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk
      Management Steps, if Approvable .............................................................................. 9

II. Summary of Chemistry Assessments .................................................................................. 9
   A. Description of the Drug Product(s) and Drug Substance(s) ........................................ 9
   B. Description of How the Drug Product is Intended to be Used .................................... 12
   C. Basis for Approvability or Not-Approval Recommendation ..................................... 12

III. Administrative .................................................................................................................... 13
   A. Reviewer’s Signature ..................................................................................................... 13
   B. Endorsement Block ...................................................................................................... 13
   C. CC Block ...................................................................................................................... 13

Chemistry Assessment ............................................................................................................ 14

I. Review Of Common Technical Document-Quality (Ctd-Q) Module 3.2: Body Of Data ........ 14
   S  DRUG SUBSTANCE [Ethyl Estradiol, Schering AG; ......................................................... 14
      Levonorgestrel, Schering AG].......................................................................................... 14
   S.1 General Information  [Ethyl Estradiol, Schering AG; .................................................. 14
      Levonorgestrel, Schering AG]......................................................................................... 14
   S.2  Manufacture [Ethyl Estradiol, Schering AG; ............................................................... 15
      Levonorgestrel, Schering AG]......................................................................................... 15
   S.3  Characterization [Ethyl Estradiol, Schering AG; ......................................................... 16
      Levonorgestrel, Schering AG]......................................................................................... 16
   S.4  Control of Drug Substance [Ethyl Estradiol, Schering AG; ........................................ 16
      Levonorgestrel, Schering AG]........................................................................................ 16
   S.5  Reference Standards or Materials [Ethyl Estradiol, Schering AG; ............................ 19
Levonorgestrel, Schering AG]..............................................................................................19
S.6 Container Closure System [Ethinyl Estradiol, Schering AG;.......................................19
Levonorgestrel, Schering AG]..............................................................................................19
S.7 Stability [Ethinyl Estradiol, Schering AG;.................................................................19
Levonorgestrel, Schering AG]..............................................................................................19
P DRUG PRODUCT [Lybrel, Oral tablet] ..............................................................................19
A APPENDICES ..................................................................................................................57
R REGIONAL INFORMATION .............................................................................................57

II. Review Of Common Technical Document-Quality (Ctd-Q) Module 1 .........................62
A. Labeling & Package Insert ..............................................................................................62
B. Environmental Assessment Or Claim Of Categorical Exclusion ..................................68

III. List Of Deficiencies To Be Communicated....................................................................68

Appears This Way
On Original
Chemistry Review Data Sheet

1. NDA 21-864

2. REVIEW #: 1

3. REVIEW DATE: 17-May-2006

4. REVIEWER: Donna F. Christner, Ph.D.

5. PREVIOUS DOCUMENTS:

<table>
<thead>
<tr>
<th>Previous Documents</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>

6. SUBMISSION(S) BEING REVIEWED:

<table>
<thead>
<tr>
<th>Submission(s) Reviewed</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original</td>
<td>27-May-2005</td>
</tr>
<tr>
<td>Amendment 003 (Withdrawn)</td>
<td>28-Nov-2005</td>
</tr>
<tr>
<td>Amendment 004 (Portions Withdrawn)</td>
<td>21-Dec-2005</td>
</tr>
<tr>
<td>Amendment 007</td>
<td>27-Jan-2006</td>
</tr>
<tr>
<td>Amendment 009</td>
<td>08-Feb-2006</td>
</tr>
<tr>
<td>Amendment 010 (Lybrel tradename)</td>
<td>10-Feb-2006</td>
</tr>
<tr>
<td>Amendment 013 (Meeting request/Level 3 change)</td>
<td>06-Mar-2006</td>
</tr>
<tr>
<td>Amendment 016 (Wyeth meeting minutes)</td>
<td>16-Mar-2006</td>
</tr>
<tr>
<td>Amendment 017 (Label icon)</td>
<td>21-Mar-2006</td>
</tr>
<tr>
<td>Amendment 019 (BCS Class 1 documentation)</td>
<td>24-Mar-2006</td>
</tr>
<tr>
<td>Amendment 022 (SUD/ClickCase Labeling)</td>
<td>29-Mar-2006</td>
</tr>
<tr>
<td>Amendment 023 (PI Labeling)</td>
<td>05-Apr-2006</td>
</tr>
<tr>
<td>Amendment 024 (Dial Pack Labeling)</td>
<td>20-Apr-2006</td>
</tr>
<tr>
<td>Amendment 026 (Reversion Meeting Request)</td>
<td>02-May-2006</td>
</tr>
</tbody>
</table>
7. NAME & ADDRESS OF APPLICANT:
   Name: Wyeth Pharmaceuticals, Inc.
   Address: PO Box 8299
            Philadelphia, PA 19101-8299
   Representative: Randall B. Bremmer
                   Associate Director II
   Telephone: 484-865-3792

8. DRUG PRODUCT NAME/CODE/TYPE:
   a) Proprietary Name: Lybrel
   b) Non-Proprietary Name (USAN): Levonorgestrel/Ethinyl estradiol
   c) Code Name/# (ONDQA only): N/A
   d) Chem. Type/Submission Priority (ONDQA only):
      - Chem. Type: 5
      - Submission Priority: S

9. LEGAL BASIS FOR SUBMISSION: 505 (b)(1)

10. PHARMACOL. CATEGORY: Oral contraceptive

11. DOSAGE FORM: Tablet (for continuous use)

12. STRENGTH/POTENCY: 90 µg Levonorgestrel (LNG)/
   20 µg Ethinyl Estradiol (EE)

13. ROUTE OF ADMINISTRATION: Oral

14. Rx/OTC DISPENSED: _x_Rx ___OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
    _____SPOTS product – Form Completed
    _x___Not a SPOTS product
16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

**Ethynyl estradiol**

![Chemical structure of Ethynyl estradiol]

- Compendial name: Ethynyl Estradiol, USP
- Chemical names: 19-Nor-17α-pregna-1,3,5(10)-triene-20-yne-3,17-diol (IUPAC)
  19-Norpregna-1,3,5(10)-triene-20-yne-3,17-diol, (17α)- (CAS)
  19-Ethynyl-estra-1,3,5(10)-triene-3,17β-diol (WHO)
  17α-Ethynyl-1,3,5(10-stratriene-3,17-diol)
- USAN: Ethynyl Estradiol
- INN: Ethinylestradiol
- Laboratory code: AY-3877
- CAS Registry No: 57-63-6
- Molecular formula: C_{20}H_{24}O_{2}
- Molecular weight: 296.40

**Levonorgestral**

![Chemical structure of Levonorgestral]

- Compendial name: Levonorgestrel, USP
- Chemical names: (-) 13β-Ethyl-17β-hydroxy-18,19-dinor-17α-pregn-4-en-20-yn-3-one (IUPAC)
  (-)-13-Ethyl-17-hydroxy-18,19-dinor-17α-pregn-4-en-20-yn-3-one (WHO)
  18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-,(17α)-(CAS Index)
- USAN: Levonorgestrel
- INN: Levonorgestrel
- Laboratory code: WY-5104
- CAS Registry No: 797-63-7
- Molecular formula: C_{21}H_{28}O_{2}
- Molecular weight: 312.45
17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER</th>
<th>ITEM REFERENCED</th>
<th>CODE</th>
<th>STATUS</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>4178</td>
<td>II</td>
<td>Schering</td>
<td>Levonorgestrel</td>
<td>1</td>
<td>Adequate</td>
<td>07-Feb-2006</td>
<td></td>
</tr>
<tr>
<td>1985</td>
<td>II</td>
<td>Schering</td>
<td>Ethinyl estradiol</td>
<td>3</td>
<td>Adequate</td>
<td>21-Nov-2005</td>
<td>Reviewed by R. Agarwal for NDA 21-871</td>
</tr>
<tr>
<td>IV</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>Adequate</td>
<td>27-Jun-2005</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td></td>
<td></td>
<td></td>
<td>3</td>
<td>Adequate</td>
<td>18-Nov-1996</td>
<td>Reviewed by R. Seelers for NDA 20-683</td>
</tr>
<tr>
<td>III</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>Adequate</td>
<td>31-Jan-2006</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td></td>
<td></td>
<td></td>
<td>4</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>Adequate</td>
<td>31-Jan-2006</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>Adequate</td>
<td>30-May-2003</td>
<td>Reviewed by L. Rocca for NDA 21-323</td>
</tr>
</tbody>
</table>

1 Action codes for DMF Table:
1 – DMF Reviewed.
Other codes indicate why the DMF was not reviewed, as follows:
2 – Type 1 DMF
3 – Reviewed previously and no revision since last review
4 – Sufficient information in application
5 – Authority to reference not granted
6 – DMF not available
7 – Other (explain under "Comments")

2 Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)
B. Other Documents:

<table>
<thead>
<tr>
<th>DOCUMENT</th>
<th>APPLICATION NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

18. STATUS:

ONDQA:

<table>
<thead>
<tr>
<th>CONSULTS/CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biometrics</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EES</td>
<td>Acceptable</td>
<td>11-Oct-2005</td>
<td>J. D’Ambrogio</td>
</tr>
<tr>
<td>Pharm/Tox</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biopharm</td>
<td>Biowaver not acceptable</td>
<td>28-Apr-2006</td>
<td>BSCS Committee</td>
</tr>
<tr>
<td>LNC</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td>Will be submitted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMETS/DDMAC</td>
<td>Tradename acceptable</td>
<td>28-Sep-2005</td>
<td>L. Wisniewski</td>
</tr>
<tr>
<td>EA</td>
<td>Granted</td>
<td>31-Mar-2006</td>
<td>D. Christner</td>
</tr>
<tr>
<td>Microbiology</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Appears This Way On Original
The Chemistry Review for NDA 21-864

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

This NDA is APPROVABLE from the CMC standpoint, pending review of data on manufacturing method and corresponding stability data. Complete data has not yet been submitted. Sponsor intends to submit data 5 days before PDUFA date.

The following information will be required for approval of the drug product:

- Information on the revised manufacturing method
- Release data on three drug product lots manufactured by the revised method
- Submission of the supportive stability data on the clinical trial supplies
- Justification for reversion to the USP dissolution method
- Supporting stability data on the approved product
- 3 months of real time and accelerated stability data on the 3 lots of drug product manufactured by the revised method.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

Not applicable.

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

Lybrel is an oral contraceptive that contains two drug substances: levonorgestrel and ethinyl estradiol. Levonorgestrel is contained in the drug product at 90 μg and ethinyl estradiol at 20μg.

The sponsor is Wyeth Pharmaceuticals. The drug substances are manufactured by Schering and information is provided in DMFs 4178 and 1985.

DRUG SUBSTANCES

Levonorgestrel
Complete information on levonorgestrel is contained in Schering’s DMF # 4178. The DMF was reviewed for this NDA and found to be adequate.

General information, General Properties, and Batch Analysis of lots used to manufacture the clinical batches are included in the NDA submission.

**Ethynyl estradiol**

Complete information on ethynyl estradiol is contained in Schering’s DMF 1985. The most recent review of the DMF was done by R. Agarwal (Review # 8, dated 21-Nov-2005) and found adequate.

General information, General Properties, and Batch Analysis of lots used to manufacture the clinical batches are included in the NDA submission.

**DRUG PRODUCT**

The drug product is a continuous-use oral contraceptive (no pill-free period). The formulation is based on the company’s approved product, Alesse, with a few changes. For the formulation, the amount of Levonorgestrel has been decreased from 100 μg to 90μg. The sponsor intended to manufacture the current drug product via a method as opposed to the method used for Alesse, although as of 02-May-2006 the sponsor plans to return to the method because of regulatory issues.

The drug product is packaged in two configurations: A Cycle Pack that is identical to that used for Alesse, and a Single Unit Dispenser. Each package holds 28 active tablets containing 90μg levonorgestrel and 20μg ethynyl estradiol. The drug product is a yellow, biconvex, film-coated tablet debossed with “W” on one side and “1117” on the other side. Excipients in the tablet core include Microcrystalline Cellulose, Lactose monohydrate, Magnesium stearate, and Polacrilin potassium. Hypromellose, Titanium Dioxide, Polyethylene glycol 400, Iron Oxide, Polyethylene glycol 1450 and Montanic Ester Wax.

The pivotal Phase 3 clinical trials were performed using tablets manufactured via a method. Another smaller Phase 3 trial was performed using some tablets manufactured by the method, and these tablets were placed on stability for determination of expiry.

Late in the review cycle (Jan 2006), Clinical determined that the smaller Phase 3 trial would not be used for determination of efficacy. Therefore, there is no bridge to show that the tablets manufactured are similar, and the sponsor has no IVIVC. The sponsor initially planned to be the manufacturing process for the commercial tablets.
The change from a method to is a Level 3 change, which would require comparative dissolution, stability studies and a bioequivalence study. Comparative dissolution and stability studies have been provided, but Wyeth requested a biowaiver for the requirement for a BE study. This request was denied. Wyeth plans to revert to the manufacturing method and submit data for review. In addition to the data, Wyeth also requests to return to the USP dissolution method for release and stability of the tablets and will provide justification for this. Wyeth plans to submit this data on 22-May-2006 and 22-Jun-2006, 5 days before the PDUFA date (27-Jun-2006).

In addition to the change from during the Phase 3 trial, the sponsor had made plans to make additional changes in the manufacturing process during the NDA review and submit these changes in an Amendment at least 3 months prior to the PDUFA date. Negotiations were held prior to NDA submission concerning the type of information that should be submitted for this change, which were submitted in Amendments dated 28-Nov-2005 and 21-Dec-2005. Although the changes should not make a difference to the quality of the product, it was determined that the minor manufacturing changes had a marked affect on the dissolution profile of the drug product on stability, resulting in the amount of levonorgestrel released, with an unknown effect on clinical efficacy. The sponsor requested a relaxation of the dissolution specification in response to this change in performance. This request was denied and the sponsor informed that expiry would be based only on the data for the batches manufactured by the original process. The sponsor withdrew the new manufacturing process and the resulting data. Therefore, expiry would be based on the submitted data for the batches manufactured by the original process. Because of the subsequent reversion to the method, determination of expiry and what to base it on is still pending.

Regulatory specifications for the tablets include Appearance & Description, Identification A (HPLC), Identification B (Melting range for LNG), Strength, Degradation products, Content Uniformity and Dissolution. Acceptance criteria are set based on the approved specifications for Alesse.

The drug product is packaged in two different configurations, the Cycle Pack and the Single Unit Dispenser (SUD). A new was used to manufacture the commercial SUD because there were impurities leaching out of the original SUD. The sponsor has provided 18 months of stability data for drug product packaged in the Cycle Pack, and 15 months of stability on drug product packaged in the Single Unit Dispenser manufactured using old, and 12 months of data on drug product packaged in the SUD manufactured using the new. The sponsor has requested 24 months of expiry based on this submitted data. All submitted stability data is on tablets manufactured by the method.
CHEMISTRY REVIEW

Executive Summary Section

Based on analysis of 18 months of real-time data in the Cycle Pack, and 15 months (old) and 12 months (new) in the SUD, along with accelerated, intermediate, and in-use stability data on tablets manufactured by the method, an expiry could be granted in both packaging configurations. This decision will have to be reevaluated in light of the reversion back and the analysis of the to-be-submitted data. Tablets are to be stored at 25°C (77°F) with excursions permitted to 15-30°C (59-86°F).

The sponsor had submitted two comparability protocols for post-approval changes:

- Comparability Protocol for Packaging of the Single Unit Dispenser
- Comparability Protocol for the Replacement or Deletion of Montanic Ester Wax

Both comparability protocols can be approved.

B. Description of How the Drug Product is Intended to be Used

Lybrel is packaged in two different configurations: the Cycle Pack and the SUD. For the Cycle Pack, a plastic tab is removed to allow rotation of the pill-containing ring. The ring is rotated to move the opening over a pill, which is then dropped into the hand. No protective blister is in place when the pills are in use. For the SUD, release of the pill is accomplished by squeezing the Dispenser to move the pill into an opening, where it is then dropped into the hand. Release of the Dispenser moves the next pill into place. As for the Cycle Pack, no protective blister is in place during use. One pill is to be taken daily, in a continuous-use regimen (no pill-free day). Each package contains 28 active tablets. After one package is finished, the next package is started the following day.

C. Basis for Approvability or Not-Approval Recommendation

The following issues must be resolved for Approval from a CMC standpoint. The PDUFA date is 27-Jun-2006.

The sponsor plans to submit the following data on 22-May-2006.

- Reversion to the manufacturing method from the method. The method is used to manufacture the approved Alesse tablets, but the sponsor has made minor changes to the method. Although it is thought that these minor changes will have no adverse impact on the quality of the drug product, and will in fact make the process more robust, data will need to be submitted and reviewed before a final decision can be made.
- CoAs for three lots of drug product manufactured by the revised method.
- Analysis of the supporting stability data (36 months) on the clinical trial supplies manufactured but stored in conventional blisters which are not one of the to-be-marketed container closure systems.
CHEMISTRY REVIEW

Executive Summary Section

- Justification to revert back to the USP dissolution method from the sponsor’s proposed method in the original NDA submission.
- Supporting data on the approved product Alesse.

The sponsor plans to submit the following data on 22-Jun-2006.

- One month of stability data on the tablets manufactured by the modified method packaged in the to-be-marketed container closure system.

Once the above data is submitted and reviewed, expiry will be determined based on the stability data already submitted on tablets manufactured by the method and stored in the to-be-marketed container closure system, the supporting data on tablets stored in conventional blisters, and data on tablets manufactured by the modified method and stored in the to-be-marketed container closure system. Supporting data on the approved Alesse product will also be taken into consideration. The sponsor has been informed in a teleconference held on 04-May-2006 that it is “highly unlikely” that the data submitted within 36 days of the PDUFA date will be reviewed during this review cycle (Clinical Division Decision). They were also informed during the teleconference that 3 months of accelerated stability data is normally required for a Level 3 manufacturing change, and that 1 month of accelerated stability data in the to-be-marketed container closure system (to be submitted on 22-Jun-2006) may not be adequate to determine expiry.

III. Administrative

A. Reviewer’s Signature

B. Endorsement Block

   Donna F. Christner, Ph.D./Date: 15-May-2006
   Moo-Jhong Rhee, Ph.D./Date
   John Kim/Date

C. CC Block

Appears This Way
On Original
This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.

/s/

Donna Christner
6/5/2006 03:17:08 PM
CHEMIST

Changes made as requested

Moo-Jhong Rhee
6/6/2006 05:08:26 PM
CHEMIST
Chief, Branch III
**NDA FILEABILITY CHECKLIST**

**NDA Number:** 21-864  **Applicant:** Wyeth Pharmaceuticals, Inc.  **Stamp Date:** 27-May-2005

**Drug Name:** Levonorgestrel(LNG)/Ethinyl Estradiol (EE) Continuous Use

**IS THE CMC SECTION OF THE APPLICATION FILEABLE? (Yes or No)**  yes

The following parameters are necessary in order to initiate a full review, i.e., complete enough to review but may have deficiencies.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Yes</th>
<th>No</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 On its face, is the section organized adequately?</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Is the section indexed and paginated adequately?</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 On its face, is the section legible?</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 Are ALL of the facilities (including contract facilities and test laboratories) identified with full street addresses and CFNs?</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 Is a statement provided that all facilities are ready for GMP inspection?</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Has an environmental assessment report or categorical exclusion been provided?</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 Does the section contain controls for the drug substance?</td>
<td>X</td>
<td>Contained in reference DMFs and NDA 20-683</td>
<td></td>
</tr>
<tr>
<td>8 Does the section contain controls for the drug product?</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 Has stability data and analysis been provided to support the requested expiration date?</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 Has all information requested during the IND phase, and at the pre-NDA meetings been included?</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 Have draft container labels been provided?</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 Has the draft package insert been provided?</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13 Has an investigational formulations section been provided?</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14 Is there a Methods Validation package?</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15 Is a separate microbiological section included?</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If the NDA is not fileable from a manufacturing and controls perspective state why it is not.

**Review-Chemist:** Donna F. Christner, Ph.D.  **Date:** 27-Jun-2005

**Team Leader:** Moo-Jhong Rhee, Ph.D.  **Date:** 27-Jun-2005

**cc:**
- Original NDA 21-864
- HFD-580/Division File
- HFD-580/Chem/Dchristner/MJRhee
- HFD-580/PM/JKim
- HFD-580/DIVDir/DSHames
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Donna Christner
7/15/05 10:57:13 AM
CHEMIST

Filing review

Moo-Jhong Rhee
7/15/05 11:25:44 AM
CHEMIST
I concur